Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07116967

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis

Sponsor: Bristol-Myers Squibb

Conditions Plaque Psoriasis

Interventions Deucravacitinib Ustekinumab

Updated 9 times since 2025 Last updated: Mar 9, 2026 Started: Sep 22, 2025 Primary completion: Jan 16, 2031 Completion: Jan 16, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Plaque Psoriasis, this trial is actively recruiting participants. The trial is conducted by Bristol-Myers Squibb and has accumulated 9 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Feb 2026 — Present [monthly]

Recruiting PHASE3
Jan 2026 — Present [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3

▶ Show 4 earlier versions

Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Ajax, Canada , Alcorcón, Spain , Anderson, United States , Arlington, United States , Asahikawa-shi, Japan , Atlanta, United States , Autonomous City of Buenos Aires, Argentina , Barrie, Canada , Beijing, China and 268 more locations